Cost-Cutting Sanofi Resumes Fitusiran Studies, Starts COVID Vaccine Phase IIb This Month
2020 Revenues Led By Dupixent, Vaccines
Dupixent was Sanofi’s top-selling product in 2020, but its vaccines division also saw significant growth in the year led by its differentiated influenza vaccines, which helped drive the big pharma’s business during the year, accompanied by significant cost savings.
